PET and MRI in the Follow-up of Neoadjuvant Chemotherapy of Breast Cancer

• Status: Completed
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

Predict and follow thanks to imaging the response to neoadjuvant chemotherapy in locally advanced breast carcinoma. Hypothesis : FLT-(18F)PET will be a predictor superior to both FDG-(18F) PET and MRI

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assistance Publique - Hôpitaux de Paris
• Collaborator: Pierre and Marie Curie University
• Treatments: Telbivudine

Criteria

Inclusion Criteria:

• Breast cancer scheduled for neoadjuvant chemotherapy followed by surgery

Exclusion criteria:

• Indicated chemotherapy without that a curative tumorectomies is foreseen(planned)

• Patient presenting an evolutionary infectious or inflammatory pathology, including an inflammatory breast cancer, being able to be source(spring) of false-positive results(profits) in TEP-FDG

• Patient in the course of radiotherapy or of chemotherapy or operated at the level of the thorax in 4 weeks preceding the date foreseen(planned) by the examination TEP (pose(installation) of implantable room(chamber) excludes)

• Diabetic waits

• Patient already includes in the other protocols of search(research) for Nuclear Medicine or for imaging using ionization radiations

• Patient not having given her lit(enlightened) assent

• Wait among which the surveillance TEP or the MRI during the chemotherapy will be impossible (that is by geographical or professional imperative, or if contraindication in the MRI, ex: port(bearing) of a pacemaker, cochlear magnetic implants, metal foreign bodies cf protocol)

• Of less than 18 years old or pregnant patient.

• Breast cancer stage(stadium) IV

• Biopsy on the already realized mammary tumor, for the period(delay) lower than 15 j.

• In case of alcoholic poisoning or of antecedents of reaction to the injection of ethanol: not inclusion to be discussed.